The discovery of EGFR-activating mutations in NSCLC and the success story of EGFR tyrosine kinase inhibitors (TKIs) have shifted the paradigm of cancer therapy from cytotoxic chemotherapy to targeted therapies [14]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.